Advancing Research
International Follicular Lymphoma Initiative
Follicular lymphoma (FL) is a slow-growing or indolent form of non-Hodgkin lymphoma (NHL) that accounts for 20 to 30 percent of all NHL cases. While typically an indolent form of lymphoma, FL remains incurable and a continuing challenge for researchers and clinicians. Although most patients respond to the current standard of care, many will require treatment throughout their lifetime; other patients’ inability to achieve a complete remission or those whose disease progresses early results in poorer long-term outcomes.
FL research has been a priority since the Foundation’s inception through research grants and convening international workshops. The Foundation’s investment expanded in 2020 when the Foundation established the Jaime Peykoff Follicular Lymphoma Initiative through the generosity of the Peykoff Family and Niagara Cares. The Foundation was able to accelerate research, convene global experts, and fund promising investigators through the $10 million dollar investment.
The Foundation’s focus in FL continues to transform the follicular lymphoma treatment landscape for tens of thousands of patients by harnessing the Lymphoma Research Foundation’s unique resources, convening the world’s experts in follicular lymphoma research and patient care, and driving direct investment in clinical research.
International Follicular Lymphoma Scientific Workshop
Building on more than two decades of experience as a convener of international scientific consortia and disease-specific research workshops, the Foundation continues to develop international scientific workshops to drive collaboration. Through these workshops, international follicular lymphoma thought leaders have the opportunity to share early research findings, discuss the results of pivotal clinical trials, and engage in planning exercises designed to advance FL research.
On December 3, 2025, the consensus recommendations from the 2024 International Follicular Lymphoma Scientific Workshop were published in Blood Advances.
Steering Committee
Chair
Ann S. LaCasce, MD, MMSC
Dana-Farber Cancer Institute
Chair
John P. Leonard, MD
NYU Langone Health
Stephen Ansell, MD, PhD
Mayo Clinic, Rochester
Carla Casulo, MD
University of Rochester Medical Center
Steven Eichberg
Chair, Foundation Board of Directors
Todd A. Fehniger, MD, PhD
Washington University School of Medicine
Loretta Nastoupil, MD
CommonSpirit Health
Laura Pasqualucci, MD
Columbia University Medical Center
Laurie Sehn, MD, MPH
BC Cancer, Vancouver
Sonali M. Smith, MD, FASCO
The University of Chicago Medical Center
John Timmerman, MD
UCLA Jonsson Comprehensive Cancer Center
Andrew D. Zelenetz, MD, PhD
Memorial Sloan Kettering Cancer Center